Literature DB >> 20219783

Autonomic nervous dysfunction development in patients with primary Sjogren's syndrome: a follow-up study.

Thomas Mandl1, Oskar Hammar, Elke Theander, Per Wollmer, Bodil Ohlsson.   

Abstract

OBJECTIVES: To investigate autonomic dysfunction (AD) development in patients with primary SS (pSS) and the associations between AD and clinical, inflammatory and serological features of pSS.
METHODS: Twenty-seven patients with pSS, who had previously been evaluated for AD, were included in the study. The patients were studied at baseline and at follow-up by objective autonomic reflex tests (ARTs) and by the autonomic symptom profile (ASP) questionnaire, evaluating AD symptoms. The median follow-up time was 5 years for the ART and 4 years for the ASP variables. The results were compared with previously investigated healthy ART controls and population-based ASP controls. Fatigue, anxiety and depression were assessed by the profile of fatigue and by the Hospital Anxiety and Depression scale.
RESULTS: Three of five ART variables as well as the ASP total score were significantly abnormal both at baseline and at follow-up in pSS patients in comparison with controls. When comparing ART and ASP results in pSS patients between baseline and follow-up, only the lowest diastolic blood pressure (lDBP) ratio significantly deteriorated during the follow-up period. The ART and ASP variables were not significantly correlated. However, the ASP total score significantly correlated with measurements of fatigue, anxiety and depression.
CONCLUSIONS: Both objective signs and subjective symptoms of parasympathetic and sympathetic dysfunction were seen in pSS patients, both at baseline and at follow-up. During follow-up, only the lDBP ratio was found to significantly deteriorate. AD symptoms were significantly associated with fatigue, anxiety and depression.

Entities:  

Mesh:

Year:  2010        PMID: 20219783     DOI: 10.1093/rheumatology/keq042

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjögren's syndrome.

Authors:  Silvia Reina; Daniela Passafaro; Leonor Sterin-Borda; Enri Borda
Journal:  Inflammopharmacology       Date:  2012-03-23       Impact factor: 4.473

2.  Adrenomedullary response to glucagon in patients with primary Sjögren's syndrome.

Authors:  Richard Imrich; Nikolay P Nikolov; Lolita Bebris; Ilias Alevizos; David S Goldstein; Courtney S Holmes; Gabor G Illei
Journal:  Cell Mol Neurobiol       Date:  2012-02-18       Impact factor: 5.046

3.  Autonomic dysfunction in primary Sjogren's syndrome: a prospective cohort analysis of 154 Korean patients.

Authors:  Jung Hee Koh; Seung-Ki Kwok; Jennifer Lee; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2016-03-25       Impact factor: 2.884

Review 4.  Sjögren's syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from Short Form 36 questionnaire and a meta-analysis.

Authors:  Qiuxiang Zhang; Xulin Wang; Haoyang Chen; Biyu Shen
Journal:  Patient Prefer Adherence       Date:  2017-05-10       Impact factor: 2.711

Review 5.  Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome.

Authors:  Kristen Davies; Wan-Fai Ng
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

6.  Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.

Authors:  Julia L Newton; James Frith; Danielle Powell; Kate Hackett; Katharine Wilton; Simon Bowman; Elizabeth Price; Colin Pease; Jacqueline Andrews; Paul Emery; John Hunter; Monica Gupta; Saravanan Vadivelu; Ian Giles; David Isenberg; Peter Lanyon; Adrian Jones; Marian Regan; Annie Cooper; Robert Moots; Nurhan Sutcliffe; Michele Bombardieri; Costantino Pitzalis; John McLaren; Steven Young-Min; Bhaskar Dasgupta; Bridget Griffiths; Dennis Lendrem; Sheryl Mitchell; Wan-Fai Ng
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.